Ian W. Mills, B.M., B.Ch., D.M.

Ian is an Entrepreneur-in-Residence on the Frazier Life Sciences team and an experienced executive in pharmaceutical development.

Ian joined the Frazier Life Sciences team as an Entrepreneur-in-Residence in March 2020. He was previously Chief Medical Officer at Outpost Medicine, a Frazier portfolio company.

Prior to Outpost, Ian was at Mitsubishi Tanabe Pharma Europe, where he was Head of Clinical Development. Prior to Mitsubishi, he was with Pfizer for more than 15 years in a variety of clinical and development leadership roles, including six years as Clinical Head of Genitourinary and Women’s Health and most recently as Vice President and Global Clinical Head for the Innovative Pharma Business. Ian has provided leadership to numerous projects across multiple therapeutic areas spanning Phases 1-4, including submission of five products for approval in major markets, and two FDA approvals.

Ian received his MA in Natural Sciences from Cambridge University and his medical degree (B.M., B.Ch.) from Oxford University. He was awarded a medical doctorate (D.M.) from Oxford for his research on the pathophysiology of overactive and neurogenic bladder. He is an accredited pharmaceutical physician and a Fellow of the Faculty of Pharmaceutical Medicine (FFPM) in the UK.

United Kingdom

Oxford University (B.M., B.Ch.)
Cambridge University (M.A.)

Year Joined

Select Investments